Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 EMRELIS IS THE FIRST AND ONLY TREATMENT APPROVED FOR PREVIOUSLY TREATED ADVANCED NSCLC PATIENTS WITH HIGH C-MET PROTEIN OVEREXPRESSION WHO OFTEN FACE POOR PROGNOSIS AND HAVE LIMITED TREATMENT OPTIONS  LUNG CANCER REMAINS THE LEADING CAUSE OF CANCER-RELATED DEATHS THROUGHOUT THE WORL D1 NORTH CHICAGO, ILL. , MAY 14, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT EMRELIS (TELISOTUZUMAB VEDOTIN-TLLV) HAS BEEN GRANTED ACCELERATED APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH C-MET PROTEIN OVEREXPRESSION (OE) WHO HAVE RECEIVED A PRIOR SYSTEMIC THERAPY.

U.S. FDA APPROVES EMRELIS (TELISOTUZUMAB VEDOTIN-TLLV) FOR ADULTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH C-MET PROTEIN OVEREXPRESSION

- COLLABORATION TO LEVERAGE ABBVIE'S EXPERTISE IN BIOTHERAPEUTIC DRUG DEVELOPMENT AND COMMERCIALIZATION TOGETHER WITH ADARX'S PROPRIETARY RNA TECHNOLOGY TO ADVANCE NEXT-GENERATION SIRNA THERAPIES ACROSS NEUROSCIENCE, IMMUNOLOGY AND ONCOLOGY NORTH CHICAGO, ILL. AND SAN DIEGO , MAY 14, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) AND ADARX PHARMACEUTICALS, A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION RNA THERAPEUTICS, TODAY ANNOUNCED A COLLABORATION AND LICENSE OPTION AGREEMENT TO DEVELOP SMALL INTERFERING RNA (SIRNA) THERAPEUTICS ACROSS MULTIPLE DISEASE AREAS, INCLUDING NEUROSCIENCE, IMMUNOLOGY AND ONCOLOGY.

ABBVIE AND ADARX PHARMACEUTICALS ANNOUNCE COLLABORATION AND LICENSE OPTION AGREEMENT TO DEVELOP NEXT-GENERATION SIRNA THERAPIES ACROSS MULTIPLE THERAPEUTIC AREAS

OXFORD, ENGLAND--(BUSINESS WIRE)-- #BIOTECH--ETCEMBLY HAS SIGNED A COLLABORATION AGREEMENT WITH DJS ANTIBODIES, A PART OF ABBVIE, TO ACCELERATE THE DISCOVERY OF NOVEL ANTIBODY THERAPEUTICS.

TECHBIO PIONEER ETCEMBLY SIGNS DEAL WITH DJS ANTIBODIES, PART OF ABBVIE, TO ACCELERATE ANTIBODY DISCOVERY PIPELINE

NEW YORK, MAY 12, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV).

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS  ABBV

NORTH CHICAGO, ILL. , MAY 6, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE BANK OF AMERICA SECURITIES HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 14, 2025.

ABBVIE TO PRESENT AT THE BANK OF AMERICA SECURITIES HEALTHCARE CONFERENCE

NEW YORK, MAY 05, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN CEREVEL THERAPEUTICS HOLDINGS, INC. ("CEREVEL THERAPEUTICS HOLDINGS, INC." OR THE "COMPANY") (NYSE: ABBV) OF A CLASS ACTION SECURITIES LAWSUIT.

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS  ABBV

NEW YORK , MAY 2, 2025 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP NOTIFIES INVESTORS IN CEREVEL THERAPEUTICS HOLDINGS, INC. ("CEREVEL THERAPEUTICS HOLDINGS, INC." OR THE "COMPANY") (NYSE: ABBV) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF CEREVEL THERAPEUTICS HOLDINGS, INC. INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD.

SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

BOTOX COSMETIC WILL PROVIDE 250 ENTREPRENEURS WITH ACCESS TO NEW RESOURCES AND OPPORTUNITIES AND WILL AWARD 20 GRANTS WORTH $20,000 EACH TO SUPPORT BUSINESS GOALS. BY 2030, BOTOX COSMETIC PLEDGES TO EMPOWER 50,000 ENTREPRENEURS, HELPING TO CLOSE THE CONFIDENCE GAP.

BOTOX COSMETIC (ONABOTULINUMTOXINA) CONTINUES ITS MISSION OF EMPOWERING ENTREPRENEURS THROUGH "THE CONFIDENCE PROJECT"

 RINVOQ (UPADACITINIB) IS NOW THE FIRST AND ONLY ORAL JANUS KINASE (JAK) INHIBITOR APPROVED FOR THE TREATMENT OF GCA IN ADULTS  ALSO KNOWN AS TEMPORAL ARTERITIS, GCA IS THE MOST COMMON VASCULITIS AFFECTING ADULTS IN WESTERN COUNTRIES 2  THIS MARKS THE NINTH APPROVED INDICATION FOR RINVOQ IN THE U.S., ACROSS RHEUMATOLOGY, GASTROENTEROLOGY, AND DERMATOLOGY1 NORTH CHICAGO, ILL. , APRIL 29, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED RINVOQ (UPADACITINIB), 15 MG, ONCE DAILY,FOR THE TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS (GCA).1 THIS COMES AFTER THE EUROPEAN COMMISSION RECENTLY GRANTED MARKETING AUTHORIZATION OF RINVOQ FOR THE TREATMENT OF GCA IN ADULT PATIENTS.

RINVOQ (UPADACITINIB) RECEIVES U.S. FDA APPROVAL FOR GIANT CELL ARTERITIS (GCA)

NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFCEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV). SHAREHOLDERS WHO PURCHASED SHARES OF ABBV DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. SHOULD CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

REPORTS FIRST-QUARTER DILUTED EPS OF $0.72 ON A GAAP BASIS, A DECREASE OF 6.5 PERCENT; ADJUSTED DILUTED EPS OF $2.46, AN INCREASE OF 6.5 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.13 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE DELIVERS FIRST-QUARTER NET REVENUES OF $13.343 BILLION, AN INCREASE OF 8.4 PERCENT ON A REPORTED BASIS OR 9.8 PERCENT ON AN OPERATIONAL BASIS FIRST -QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $6.264 BILLION, AN INCREASE OF 16.6 PERCENT ON A REPORTED BASIS, OR 18.1 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $3.425 BILLION; GLOBAL RINVOQ NET REVENUES WERE $1.718 BILLION; GLOBAL HUMIRA NET REVENUES WERE $1.121 BILLION  FIRST-QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $2.282 BILLION, AN INCREASE OF 16.1 PERCENT ON A REPORTED BASIS, OR 17.0 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $765 MILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $866 MILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $433 MILLION  FIRST-QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.633 BILLION, AN INCREASE OF 5.8 PERCENT ON A REPORTED BASIS, OR 7.5 PERCENT ON AN OPERATIONAL BASIS; GLOBAL IMBRUVICA NET REVENUES WERE $738 MILLION; GLOBAL VENCLEXTA NET REVENUES WERE $665 MILLION; GLOBAL ELAHERE NET REVENUES WERE $179 MILLION  FIRST -QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.102 BILLION, A DECREASE OF 11.7 PERCENT ON A REPORTED BASIS, OR 10.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $556 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $231 MILLION  RAISES 2025 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $11.99 - $12.19 TO $12.09 - $12.29, WHICH INCLUDES AN UNFAVORABLE IMPACT OF $0.13 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE INCURRED YEAR-TO-DATE THROUGH THE FIRST QUARTER 2025 NORTH CHICAGO, ILL. , APRIL 25, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE:ABBV) ANNOUNCED FINANCIAL

ABBVIE REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS

NEW YORK, NY / ACCESS NEWSWIRE / APRIL 24, 2025 / IF YOU SUFFERED A LOSS ON YOUR CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE:ABBV) INVESTMENT AND WANT TO LEARN ABOUT A POTENTIAL RECOVERY UNDER THE FEDERAL SECURITIES LAWS, FOLLOW THE LINK BELOW FOR MORE INFORMATION: HTTPS://ZLK.COM/PSLRA-1/CEREVEL-THERAPEUTICS-HOLDINGS-INC-LAWSUIT-SUBMISSION-FORM?PRID=144878&WIRE=1 OR CONTACT JOSEPH E. LEVI, ESQ.

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

TRENIBOTE IS A FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E CHARACTERIZED BY A RAPID ONSET OF ACTION AS EARLY AS 8 HOURS AFTER ADMINISTRATION (EARLIEST ASSESSMENT TIME) AND SHORTER DURATION OF EFFECT OF 2-3 WEEKS.  IF APPROVED, TRENIBOTE WILL BE THE FIRST NEUROTOXIN OF ITS KIND AVAILABLE TO PATIENTS.

ABBVIE SUBMITS BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR TRENIBOTULINUMTOXINE (TRENIBOTE) FOR THE TREATMENT OF GLABELLAR LINES

NEW YORK, APRIL 23, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV).

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS  ABBV

NEW YORK, NY / ACCESS NEWSWIRE / APRIL 11, 2025 / IF YOU SUFFERED A LOSS ON YOUR CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE:ABBV) INVESTMENT AND WANT TO LEARN ABOUT A POTENTIAL RECOVERY UNDER THE FEDERAL SECURITIES LAWS, FOLLOW THE LINK BELOW FOR MORE INFORMATION: HTTPS://ZLK.COM/PSLRA-1/CEREVEL-THERAPEUTICS-HOLDINGS-INC-LAWSUIT-SUBMISSION-FORM?PRID=142536&WIRE=1 OR CONTACT JOSEPH E. LEVI, ESQ.

RINVOQ IS THE FIRST AND ONLY ORAL JANUS KINASE (JAK) INHIBITOR APPROVED IN THE EUROPEAN UNION (EU) TO TREAT ADULT PATIENTS WITH GIANT CELL ARTERITIS (GCA) THE APPROVAL IS SUPPORTED BY DATA FROM THE PIVOTAL PHASE 3 SELECT-GCA TRIAL WHICH DEMONSTRATED THAT RINVOQ ACHIEVED THE PRIMARY ENDPOINT OF SUSTAINED REMISSION* AND KEY SECONDARY ENDPOINTS, INCLUDING REDUCTION IN DISEASE FLARES, LOWER CUMULATIVE STEROID EXPOSURE AND COMPLETE REMISSION 1 THIS MARKS THE EIGHTH APPROVED INDICATION FOR RINVOQ IN THE EU2 NORTH CHICAGO, ILL. , APRIL 8, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) GRANTED MARKETING AUTHORIZATION TO RINVOQ (UPADACITINIB; 15 MG, ONCE DAILY) FOR THE TREATMENT OF GIANT CELL ARTERITIS (GCA) IN ADULT PATIENTS.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS

NORTH CHICAGO, ILL. , MARCH 31, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL ANNOUNCE ITS FIRST-QUARTER 2025 FINANCIAL RESULTS ON FRIDAY, APRIL 25, 2025, BEFORE THE MARKET OPENS.

ABBVIE TO HOST FIRST-QUARTER 2025 EARNINGS CONFERENCE CALL

HRSHOLM, DK / ACCESS NEWSWIRE / MARCH 28, 2025 / GUBRA (CPH:GUBRA) WITH REFERENCE TO ABBVIE'S (NYSE:ABBV) AND GUBRA A/S' (CPSE:GUBRA) JOINT ANNOUNCEMENT OF MARCH 3, 2025 REGARDING A LICENSE AGREEMENT TO DEVELOP GUB014295, A POTENTIAL BEST-IN-CLASS, LONG-ACTING AMYLIN ANALOG FOR THE TREATMENT OF OBESITY, THE US FEDERAL TRADE COMMISSION TODAY GRANTED EARLY TERMINATION OF THE WAITING PERIOD UNDER THE HSR ACT. CLOSING OF THE LICENSE AGREEMENT REMAINS SUBJECT TO OTHER CUSTOMARY CLOSING CONDITIONS.

REGULATORY CONDITION SATISFIED FOR LICENSE AGREEMENT BETWEEN ABBVIE AND GUBRA

DATA FOR ABBV-969, A NOVEL STEAP1/PSMA DUAL-TARGETED ANTIBODY-DRUG CONJUGATE (ADC) IN PHASE 1 FOR ADVANCED PROSTATE CANCER, WILL BE PRESENTED IN AN ORAL PRESENTATION. DATA TO BE PRESENTED ON ABBV-514, A NOVEL CCR8 TARGETING ANTIBODY, IN PHASE 1 FOR NON-SMALL CELL LUNG CANCER, HEAD AND NECK CANCER AND OTHER SOLID TUMORS.

AbbVie Inc.

ABBV

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

ABBV